Ipsen's fourth-quarter buoyed by strong North American and rest of world sales
This article was originally published in Scrip
Ipsen's fourth-quarter revenues increased by 8% to €255.3 million despite falling sales in France and the UK.
The decline in the two countries drove Ipsen's sales in major western European countries down by 2% to €142.8 million. The drop in France was due to lower sales of the laxative Forlax (macrogol) following the launch of a generic version in March, as well as for two six-month formulations of the prostate cancer treatment Decapeptyl (triptorelin acetate).
In the UK, sales dropped by 1% due to a strong impact from negative foreign currency exchange. Excluding foreign exchange impacts, sales in the country increased by 9%.
However, sales in other areas more than made up for this decline. The greatest growth in the quarter was seen in the North America, where sales rose by 73% to €12.1 million. Sales in other European countries and the rest of the world increased by 15% to €58.5 million and 27% to €41.9 million, respectively.
Ipsen's highest selling product was Decapeptyl, which was up by 1% to €58.5 million. The muscle relaxant Dysport (botulinum toxin) increased in sales by 41% to €45.1 million while the anticancer Somatuline (lanreotide) rose by 19% to €36.5 million.
Ipsen's full-year sales increased by 6% to €971 million, driven by North American sales increasing by more than four-fold to €46 million and rest of the world sales rising by 21% to €198.2 million.